An international centre for clinical trials has been established At MVR Cancer Centre & Research Institute Hospital not only to initiate clinicians in the concept of scientific and evidence-based medicine but also to address
burning medical and epidemiological questions in which the west is unlikely to have any interest. Scientific leads from laboratory ultimately need to be answered in human subjects in the form of a randomized clinical
trial. But, due to a lack of understanding as to how such a question should be addressed in a clinical setting and a lack of interaction between the clinician and the laboratory scientist, many important scientific
leads are lost by default. The scientific community, other funding agencies and ultimately patients may benefit from testing the efficacy of newly synthesized biological products such as engineered enzymes, genetic
materials and other substances emanating from laboratories. In the sphere of public health, where very large community initiatives are a norm, would benefit from having a centralized facility to conduct trials involving
thousands of subjects. The randomized clinical trial offers a unique opportunity to test these issues scientifically before they are sanctioned for routine health care.
List of ongoing clinical trials (recruitment phase)
| SL N | Name of the clinical trial | Sponsor |
|---|---|---|
| 1 | A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) |
Astrazeneca |
| 2 | SERENA-4
A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received |
Astrazeneca |
| 3 | RI-01-006
Randomised, Double-Blind, Parallel-Group, Phase Iii Study To Compare The Efficacy, Safety, And Immunogenicity Of Proposed Rituximab Biosimilar (Drl_Ri) With Mabthera In Subjects With Previously Untreated, Stage Ii-Iv, Cd20+, Low Tumour Burden Follicular |
Dr Reddy’s Laboratories |
| 4 | A Multicenter, Randomised, Double blind, Parallel, Phase III Global Study to Assess the Efficacy and Safety of BP01 (Bevacizumab) when compared to Avastin®-EU In Combination with Carboplatin and Paclitaxel during Induction Phase and Bevacizumab Alone during the Maintenance Phase. In patients with Newly diagnosed or Recurrent Stage IIIB/IV Non-Squamous (ns) Non-Small Cell Lung Cancer (NSCLC). |
Axis Clinicals – Curatech Biologicals (Aurobindo Pharma) |
| 5 | A single-arm, open-label Phase 4 study of darolutamide in addition to standard androgen deprivation therapy for Indian participants with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) | Bayer Pharmaceuticals |
| 6 | Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) . | Astrazeneca |
| 7 | A Phase Iii, Randomized, Open-Label Study Of Pralsetinib Versus Standard Of Care For First-Line Treatment Of Ret Fusion-Positive, Metastatic Non-Small Cell Lung Cancer | Roche Products |
| 8 | Randomized, Open Label, Multicenter, Phase Iii Study Of Entrectinib Versus Crizotinib In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer Harboring Ros1 Gene Rearrangements With And Without Central Nervous System Metastases” |
Roche Products |
| 9 | A phase iii, randomized, double-blind, placebo controlled, multi-center, international study of durvalumab given concurrently with definitive chemoradiation therapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma (KUNLUN) |
Astrazeneca |
| 10 | A phase iii, open-label, randomised study of datopotamab Deruxtecan (dato-dxd) in combination with durvalumab Compared with investigator’s choice of chemotherapy (paclitaxel, nab-paclitaxel or gemcitabine + carboplatin) in Combination with pembrolizumab in patients with pd-l1 Positive locally recurrent inoperable or metastatic Triple-negative breast cancer (TROPION-BREAST05) |
Astrazeneca |
| 11 | A phase iii, randomised, open-label, multicentre, global study of datopotamab deruxtecan (dato- Dxd) in combination with durvalumab and carboplatin versus pembrolizumab in combination with platinum Based chemotherapy for the first-line treatment of patients with locally advanced or metastatic nsclc Without actionable genomic alterations (D926NC00001; AVANZAR) |
Astrazeneca |
